Daiichi Sankyo to Cut 1200 US Jobs
October 19, 2015.
Daiichi Sankyo will "reorganize its U.S. Commercial organization as it transfers to a differentiated specialty portfolio that will include areas such as cardiovascular, pain management and oncology", the company has announced.
The company says it "will reduce expenses, including a reduction in headcount, from its U.S. Commercial operations". It expects to eliminate 1,000 to 1,200 positions across the country, from the Commercial Home Office, located in Parsippany, NJ, and field-based sales and other positions throughout the country. The company added that the reorganization is not focused on the U.S.-based R&D function concentrated in Edison, NJ, or the packaging plant in Bethlehem, PA.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
